[4-(溴甲基)苯基]-环丙基甲酮 | 35981-66-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: [4-(溴甲基)苯基]-环丙基甲酮
• 中文别名: (4-(溴甲基)苯基)(环丙基)甲酮
• 英文名称: (4-Bromomethyl-phenyl)-cyclopropyl-methanone
• 英文别名: α-Brom-p-tolyl-cyclopropylketon；p-Cyclopropyl-carbonyl-benzylbromid；(4-(Bromomethyl)phenyl)(cyclopropyl)methanone；[4-(bromomethyl)phenyl]-cyclopropylmethanone
• CAS: 35981-66-9
• 化学式: C₁₁H₁₁BrO
• 分子量: 239.112
• InChiKey: RWDFDRURELYOOX-UHFFFAOYSA-N

物化性质

• 沸点：
  336.5±25.0 °C(Predicted)
• 密度：
  1.496±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914700090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P501,P260,P264,P280,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  [4-(溴甲基)苯基]-环丙基甲酮 在 氢氧化钾 、 乙醇 作用下， 生成 4-(cyclopropylcarbonyl)-benzeneacetic acid,methyl ester
  参考文献：
  名称：

  （-环丙基-对甲苯基）乙酸及相关化合物的合成及抗炎活性。

  摘要：

  DOI：

  10.1021/jm00263a015
• 作为产物：
  描述：

  环丙基(4-甲基苯基)-甲酮 在 N-溴代丁二酰亚胺(NBS) 作用下， 生成 [4-(溴甲基)苯基]-环丙基甲酮
  参考文献：
  名称：

  （-环丙基-对甲苯基）乙酸及相关化合物的合成及抗炎活性。

  摘要：

  DOI：

  10.1021/jm00263a015

文献信息

• Intermediates useful for the preparation of antihistaminic piperidine derivatives
  申请人：Merrell Pharmaceuticals, Inc.

  公开号：US06348597B2

  公开（公告）日：2002-02-19

  The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula wherein W represents —C(═O)— or —CH(OH)—; R1 represents hydrogen or hydroxy; R2 represents hydrogen; R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; m is an integer 0 or 1; R3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R1 and R2 are taken together to form a second bond between the carbon atoms bearing R1 and R2 or where R1 represented hydroxy, m is an integer 0.

  本发明涉及一种新型中间体和过程，该中间体和过程在制备某些抗组胺酸哌啶衍生物的过程中非常有用，其化学式为 其中 W代表—C(═O)—或—CH(OH)—; R1代表氢或羟基; R2代表氢; R1和R2一起形成连接R1和R2的碳原子之间的第二键; n为1至5的整数; m为0或1的整数; R3为—COOH或—COO烷基，其中烷基基团具有1至6个碳原子，直链或支链，A的每个是氢或羟基;以及其药用可接受盐和各自的光学异构体， 但是当R1和R2一起形成连接R1和R2的碳原子之间的第二键或当R1代表羟基时，m为0。
• [EN] Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile<br/>[FR] PROCÉDÉ POUR LA PRODUCTION DE 2-[4-(CYCLOPROPANECARBONYL)PHÉNYL]-2-MÉTHYL-PROPANENITRILE
  申请人：SANOFI AVENTIS DEUTSCHLAND

  公开号：WO2016116555A1

  公开（公告）日：2016-07-28

  A new process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl- propanenitrile is described. This compound can be used for the production of drugs, such as Fexofenadine.

  描述了一种生产2-[4-(环丙基甲酰基)苯基]-2-甲基丙腈的新工艺。这种化合物可用于生产药物，如非索非丁。
• AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
  申请人：SANOFI

  公开号：US20180237419A1

  公开（公告）日：2018-08-23

  The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本公开涉及氮杂环丙烷化合物。这些氮杂环丙烷化合物是GPR119调节剂，对于预防和/或治疗糖尿病、肥胖、血脂异常及相关疾病具有用处。此外，本公开还涉及将氮杂环丙烷化合物用作药物中的活性成分，以及包含它们的药物组合物。
• Intermediates useful for the preparation of antihistaminic piperidine
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US06147216A1

  公开（公告）日：2000-11-14

  The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula ##STR1## wherein W represents --C(.dbd.O)-- or --CH(OH)--; R.sub.1 represents hydrogen or hydroxy; R.sub.2 represents hydrogen; R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; m is an integer 0 or 1; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R.sub.1 and R.sub.2 are ta to form a second bond between the carbon R.sub.1 and R.sub.2 or where R.sub.1 represented hydroxy integer 0.

  本发明涉及一种新型中间体和工艺，可用于制备某些抗组胺酸哌啶衍生物，其化学式为##STR1##其中W代表--C(.dbd.O)--或--CH(OH)--；R.sub.1代表氢或羟基；R.sub.2代表氢；R.sub.1和R.sub.2共同形成连接R.sub.1和R.sub.2的碳原子之间的第二键；n为1至5的整数；m为0或1的整数；R.sub.3为--COOH或--COOalkyl，其中alkyl基含有1至6个碳原子，是直链或支链；每个A都是氢或羟基；以及其药用盐和单体光学异构体，但其中R.sub.1和R.sub.2形成连接R.sub.1和R.sub.2的碳原子之间的第二键或R.sub.1代表羟基时除外。
• Substituted imidazoles
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20030181479A1

  公开（公告）日：2003-09-25

  The present invention relates to novel substituted imidazoles, to the use of these compounds as medicaments, to pharmaceutical compositions comprising the compounds, and to a method of treatment employing these compounds and compositions. The present compounds show a high and selective binding affinity to the histamine H3 receptor indicating a histamine H3 receptor antagonistic or agonistic activity. As a result, the compounds are useful for the treatment of disorders related to the histamine H3 receptor. More particularly, the present compounds possess a histamine H3 receptor agonistic activity and are accordingly useful in the treatment of disorders in which a histamine H3 receptor activation is beneficial.

  本发明涉及新型取代咪唑，以及这些化合物作为药物的使用，包括含有这些化合物的制药组合物和使用这些化合物和组合物的治疗方法。这些化合物表现出高度选择性的结合亲和力，指示组合物具有组胺H3受体拮抗或激动活性。因此，这些化合物可用于治疗与组胺H3受体有关的疾病。更具体地，这些化合物具有组胺H3受体激动活性，因此可用于治疗组胺H3受体激活有益的疾病。